Psychopharmacology of Autistic Spectrum Disorders in Children and Adolescents

Pediatric Clinics of North America

Volumn 58, Issue 1, 2011, Pages 85-97

  Nazeer, Ahsan ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Aggression; Anxiety; Autism; Compulsion; Psychopharmacology; Ritualistic behavior; Stereotypes

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; CLONIDINE; ETIRACETAM; FLUOXETINE; FLUPHENAZINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ADOLESCENT; AGGRESSION; AGITATION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; AUTOMUTILATION; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CHILD; CHILD PSYCHIATRY; COMORBIDITY; COMPULSION; CONDUCT DISORDER; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHORIA; DYSTONIA; DYSTONIC DISORDER; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPOTENSION; IMPULSE CONTROL DISORDER; IMPULSIVENESS; INCREASED APPETITE; INFANTILE AUTISM; IRRITABILITY; LIPID BLOOD LEVEL; LOW DRUG DOSE; MANIA; MOTOR DYSFUNCTION; NAUSEA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATIENT MONITORING; PERSONALITY DISORDER; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; PSYCHOSOCIAL WITHDRAWAL; REVIEW; SEDATION; SIDE EFFECT; SOCIAL AVOIDANCE BEHAVIOR; SUICIDE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WITHDRAWAL SYNDROME;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS;

EID: 79251557516     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.10.011     Document Type: Review

References (57)

1. Kanner L. Autistic disturbances of affective contact. Nerv Child 1943, 2:217-250.
2. Bleuler E. The theory of schizophrenic negativism. Nervous and mental disease monograph series no. 11. Translated by William A. White (MD) 1912, The Journal of Nervous and Mental Disease Publishing Company, New York.
3. Rutter M. Concepts of autism: a review of research. J Child Psychol Psychiatry 1968, 9(1):1-25.
4. Rutter M. Diagnosis and definition. Autism: a reappraisal of concepts and treatment 1978, Plenum Press, New York. M. Rutter, E. Schopler (Eds.).
5. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1987, American Psychiatric Publishing;, Washington. 3rd edition.
6. American Psychiatric Association DSM-V development 2010, APA;, Washington.
7. Ghaziuddin M., Tsai L., Ghaziuddin N. Comorbidity of autistic disorder in children and adolescents. Eur Child Adolesc Psychiatry 1992, 1(4):209-213.
8. Simonoff E., Pickles A., Charman T. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 2008, 47(8):921-929.
9. Schreibman L. Intensive behavioral/psychoeducational treatments for autism: research needs and future directions. J Autism Dev Disord 2000, 30:373-378.
10. Frazier T.W., Youngstrom E.A., Haycook T., et al. Effectiveness of medication combined with intensive behavioral intervention for reducing aggression in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol 2010, 20(3):167-177.
11. Parikh M.S., Kolevzon A., Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 2008, 18:157-178.
12. Anderson L.T., Campbell M., Grega D.M., et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984, 141:1195-1202.
13. Malone R.P., Gratz S.S., Delaney M.A., et al. Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs 2005, 19:923-934.
14. Research Units on Pediatric Psychopharmacology Autism Network Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005, 162:1361-1369.
15. Food and Drug Administration FDA approves the first drug to treat irritability associated with autism, risperdal 2006, FDA News, Available at:, Accessed June 14, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm.
16. Campbell M., Anderson L.T., Meier M., et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Adolesc Psychiatry 1978, 17(4):640-655.
17. Pierre J.M. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005, 28:191-208.
18. Research Units on Pediatric Psychopharmacology Autism Network (RUPPAN) Risperidone in children with autism for serious behavioral problems. N Engl J Med 2002, 347:314-321.
19. Masi G., Cosenza A., Mucci M., et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003, 64:1039-1047.
20. Luby J., Mrakotsky C., Stalets M.M., et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006, 16:575-587.
21. Hollander E., Wasserman S., Swanson E.N., et al. A double blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006, 16(5):541-548.
22. Owen R., Sikich L., Marcus R., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124(6):1533-1540.
23. Marcus R.N., Owen R., Kamen L., et al. A placebo-controlled, fixed dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48(11):1110-1119.
24. Malone R.P., Delaney M.A., Hyman S.B., et al. Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 2007, 17(6):779-790.
25. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21:151-156.
26. Mackin P., Watkinson H.M., Young A.H. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 2005, 48:215-221.
27. Schain R.J., Freedman D. Studies on 5-hydroxyindole metabolism in autistic disorder and other mentally retarded children. J Pediatr 1961, 58:315-320.
28. Williams K., Wheeler D.M., Silove N., et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010, 8. CD004677.
29. Jaselskis C.A., Cook E.H., Fletcher K.E., et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992, 12:322-327.
30. Posey D.J., Puntney J.I., Sasher T.M., et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 2004, 14(2):233-241.
31. Quintana H., Birmaher B., Stedge D., et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995, 25:283-294.
32. Handen B.L., Johnson C.R., Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000, 30:245-255.
33. Kafantaris V., Campbell M., Padron-Gayol M.V., et al. Carbamazepine in hospitalized aggressive conduct disorder children: an open pilot study. Psychopharmacol Bull 1992, 28(2):193-199.
34. Malone R.P., Delaney M.A., Luebbert J.F., et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000, 57(7):649-654.
35. Carlson G.A., Rapport M.D., Pataki C.S., et al. Lithium in hospitalized children at 4 and 8 weeks: mood, behavior and cognitive effects. J Child Psychol Psychiatry 1992, 33(2):411-425.
36. Hellings J.A., Weckbaugh M., Nickel E.J., et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005, 15:682-692.
37. Hollander E., Chaplin W., Soorya L., et al. Divalproex sodium vs. placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology 2010, 35(4):990-998.
38. Belsito K.M., Law P.A., Kirk K.S., et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001, 31:175-181.
39. Wasserman S., Iyengar R., Chaplin W.F., et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2006, 21(6):363-367.
40. Goldstein S., Schebach A.J. The comorbidity of pervasive developmental disorder and attention disorder: results of a retrospective chart review. J Autism Dev Disord 2004, 34(3):329-339.
41. Reiersen A.M., Constantino J.N., Grimmer M., et al. Evidence for shared genetic influences on self-reported ADHD and autistic symptoms in young adult Australian twins. Twin Res Hum Genet 2008, 11:579-585.
42. Reiersen A.M., Todd R.D. Co-occurrence of ADHD and autism spectrum disorders: phenomenology and treatment. Expert Rev Neurother 2008, 8(4):657-669.
43. Hazell P. Drug therapy for attention-deficit hyperactivity disorder-like symptoms in autistic disorder. J Paediatr Child Health 2007, 43(1-2):19-24.
44. Research Units on Pediatric Psychopharmacology Autism Network A randomized, double-blind, placebo controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Arch Gen Psychiatry 2005, 62:1266-1274.
45. Posey D.J., Aman M.G., McCracken J.T., et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007, 61(4):538-544.
46. Arnold L.E., Aman M.G., Cook A.M., et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006, 45(10):1196-1205.
47. Fankhauser M.P., Karumanchi V.C., German M.L., et al. Double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992, 53(3):77-82.
48. Scahill L., Aman M.G., McDougle C.J., et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006, 16(5):589-598.
49. Santosh P.J., Baird G., Pityaratstian N., et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006, 32(5):575-583.
50. Militerni R., Bravaccio C., Falco C., et al. Repetitive behaviors in autistic disorder. Eur Child Adolesc Psychiatry 2002, 11(5):210-218.
51. McDougle C.J., Kresch L.E., Goodman W.K., et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 1995, 152(5):772-777.
52. King B.H., Hollander E., Sikich L., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66(6):583-590.
53. Soorya L., Kiarashi J., Hollander E. Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008, 17(4):753-771.
54. Anagnostou E., Hollander E. Treatment of repetitive behaviors in autism. Curr Psychiatr 2006, 5:55-64.
55. Hollander E., Phillips A., Chaplin W., et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 2005, 30:582-589.
56. McDougle C.J., Scahill L., Aman M.G., et al. Risperidone for the core symptom domains of autism: results from the study by autism network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005, 162:1142-1148.
57. Hollander E., Soorya L., Wasserman S., et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol 2006, 9(2):209-213.